Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin ASilvana Mourón, Miguel Quintela-Fandiño, Noelia Martínez-Jáñez et al.|Nature Communications|2022Cited by 14
22P HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysisRodrigo Sánchez-Bayona, Eva Ciruelos, A.M. Castro Luna et al.|Annals of Oncology|2021Cited by 13
Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancerRodrigo Sánchez-Bayona, Pablo Tolosa, Santiago Terán et al.|Cancer Research|2022Cited by 4
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancerRebeca Jimeno, Miguel Quintela-Fandiño, Silvana Mourón et al.|Clinical & Translational Oncology|2022Cited by 1